Studies using genetically engineered mouse models have shown that ARID1A deficiency leads to increases in tumour infiltrating lymphocytes (TILs), immune checkpoint activation and subsequent sensitisation to PD‐L1 checkpoint blockade, due to a proposed loss of interaction with the mismatch repair (MMR) protein MSH2 [1]. Here, ARID1A is linked to neoplasm.